logo-loader

Tesla stock goes into reverse in pre-market after Canaccord downgrade

Published: 09:34 05 Feb 2020 EST

Tesla Inc -
Tesla shares have zoomed up around 106% in the year to date and are not far off the US$900 mark

Tesla (NASDAQ:TSLA) shares came off the boil before the bell in New York after broker Canaccord downgraded the electric car giant to Hold from Buy. 

Analysts there reckon investors should wait before buying the stock after the barnstorming share rally Elon Musk's firm has enjoyed. 

Tesla shares have zoomed up around 106% in the year to date and are not far off the US$900 mark. Yesterday, the stock surged 17% on the back of an eye-watering 20% surge the day before. 

READ: Tesla puts the pedal to the floor as quarterly earnings top estimates

It comes after two impressive quarterly earnings reports in a row. Tesla, which late last year became the planet's largest electric vehicle (EV) manufacturer, has now risen over 3,000% over the past decade.

"While we continue to favor TSLA as the leading EV juggernaut and believe the April battery day will be a critical positive milestone for investors to understand how formidable the lead is that TSLA holds, we believe patient investors will likely get a more attractive entry point," said Canaccord analyst Jed Dorsheimer.

The analyst did hike his Tesla stock target to US$750, but that was considerably below Tuesday's record close of US$887.06.

The Chinese coronavirus is also putting the brakes on optimism. A company executive has revealed that cars initially scheduled for delivery in early February will be delayed due to the outbreak of the killer virus.

Tesla began rolling out Model 3s from its Shanghai Gigafactory to Chinese customers, a potentially huge market, this month but has kept the plant closed after the Lunar New Year following Chinese government guidelines.

"Just as we observed a clear buy signal coming into 2020, we see the risk of China's coronavirus as a clear headwind to the Shanghai facility, suggesting a more pragmatic position," said Canaccord analyst Dorsheimer.

Tesla shares dropped 3.61% in pre-market to US$855 each.

Contact the author at giles@proactiveinvestors.com

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 31 minutes ago